Company intelligence / Profile preview

Dermelix Biotherapeutics

New York, New York, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Dermelix is developing DMX-101, a novel in utero protein replacement therapy for XLHED that has received Orphan Drug Designation in the US and benefits from accelerated development under EMA's PRIME scheme in Europe. They also have DMX-102 in discovery phase for Netherton Syndrome.

Therapeutic areas: DermatologyRare Diseases
Modalities: Protein replacement therapyAntisense oligonucleotide (ASO)Fusion protein
Industry: Biotech

Drug pipeline

3 assets

cavrotolimod

Phase 2

Indications: Merkel cell carcinoma, Cutaneous squamous cell carcinoma

2 more assets in the full pipeline.

Request access →

Partnerships

EspeRare (for DMX-101)Exicure Inc. (originator of DMX-102)

Beyond the preview

Go deeper on Dermelix Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dermelix Biotherapeutics.

Explore the full profile